NCT05489211 2026-03-19Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)AstraZenecaPhase 2 Recruiting454 enrolled
NCT04300556 2026-03-13A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesEisai Inc.Phase 1/2 Recruiting182 enrolled